Current Report Filing (8-k)
May 20 2016 - 2:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): May 16, 2016
DELMAR PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Nevada
|
|
000-54801
|
|
99-0360497
|
(State or Other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification Number)
|
|
|
|
|
|
Suite 720-999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5
(Address of principal executive offices)
(zip code)
(604) 629-5989
(Registrant's
telephone number, including area code)
Copies to:
Gregory Sichenzia, Esq.
Jeff Cahlon, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway
New York, New York 10006
Phone: (212) 930-9700
Fax: (212) 930-9725
(Former address,
if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On
May 16, 2016, the Company filed a Certificate of Change with the Secretary of State of Nevada. Pursuant to the Certificate of
Change, the Company effected a four-for-one reverse split (the “Reverse Split”) of its outstanding common stock, and
the number of authorized shares of common stock was correspondingly reduced from 200,000,000 to 50,000,000.
The
Reverse Split became effective in the market at the open of business on May 20, 2016.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
3.1
|
|
Certificate of Change filed with the Nevada Secretary of State on May 16, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
DELMAR PHARMACEUTICALS, INC.
|
|
|
|
Dated: May 20, 2016
|
By:
|
/s/ Jeffrey Bacha
|
|
|
Name: Jeffrey Bacha
|
|
|
Title: Chief Executive Officer
|
|
|
|
DelMar Pharmaceuticals (NASDAQ:DMPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
DelMar Pharmaceuticals (NASDAQ:DMPI)
Historical Stock Chart
From Sep 2023 to Sep 2024